Telisotuzumab vedotin
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein[1][2].
Product Specifications
CAS Number
[1714088-51-3]
Product Name Alternative
ABBV-399
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; c-Met/HGFR
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/telisotuzumab-vedotin.html
Purity
99.81
Solubility
DMSO : ≥ 100 mg/mL
Smiles
[Telisotuzumabvedotin]
Molecular Weight
145000 (average)
References & Citations
[1]Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36 (33) :3298-3306. |[2]Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41 (5) : 1105-1115.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
